March 25, 2023

The Queens County Citizen

Complete Canadian News World

Emergency approval for the Indian vaccine Kovovax

Emergency approval for the Indian vaccine Kovovax

(Geneva) The World Health Organization (WHO) on Friday approved the Indian anti-COVID-19 vaccine Covovax, which is manufactured under the authority of the US pharmaceutical manufacturer and facilitates access to vaccines in poorer countries.

This vaccine is manufactured under the license of “Serum Institute of India” [l’américain] Novovax and it is part of the COVAX portfolio [le système international de distribution de vaccins anti-COVID-19, NDLR], Which will help boost immunization efforts for more people in low-income countries, ”the WHO said in a statement.

“Despite the appearance of new mutations, vaccines are still one of the most effective methods to protect against the severe forms and deaths caused by SARS-COV-2,” Dee said.R Mariangela Simao, WHO Access to Medicines Officer.

The approval should make vaccines available to poorer countries, of which 41 countries have not yet vaccinated 10% of their population, while 98% of countries have not yet reached 40%, she pointed out.

The WHO aims to vaccinate 40% of the population of all countries by the end of this year.

The vaccine requires two doses and can be stored at 2 to 8 ° C, such as in commercial refrigerators.

It uses a technology that is different from the technology already in place for the widely used vaccines in the world. It is a so-called “subunit” vaccine based on proteins that stimulate the immune response without viruses.

It includes anti-COVID-19 covalent vaccines from Indian India Biotech, Pfizer-Biontech, Modernna, AstraZeneca (WHO has two AZ vaccines, one of which is made in India), Johnson & Johnson, Synoform and Sinovax. Emergency approvals.

READ  Road works | Weekend restrictions

The WHO Expert Committee on Immunization has not yet clarified the recommended age for vaccination.

Covovax is taken from Nuvaxovid, for which marketing authority has been submitted to the European Medicines Agency, which will make a decision next week.

WHO approval facilitates international recognition of the vaccine and, especially for UN agencies and the COVAX system – designed to facilitate vaccination in poorer countries – to use it.